ArticleACS medicinal chemistry letters2017
Structure Optimization of Aloperine Derivatives as HIV-1 Entry Inhibitors.
Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Aloperine Inhibits ASFV via Regulating PRLR/JAK2 Signaling Pathway In Vitro.International journal of molecular sciences · 2024Article
- Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors.International journal of molecular sciences · 2022Article
- Aloperine: A Potent Modulator of Crucial Biological Mechanisms in Multiple Diseases.Biomedicines · 2022Review
- Aloperine inhibits the progression of non-small-cell lung cancer through the PI3K/Akt signaling pathway.Cancer cell international · 2021Article
- Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors.Current medicinal chemistry · 2021Article
- A Review on Recent Advances in Aloperine Research: Pharmacological Activities and Underlying Biological Mechanisms.Frontiers in pharmacology · 2020Review
- Autophagy Modulation in Human Thyroid Cancer Cells following Aloperine Treatment.International journal of molecular sciences · 2019Article
- Identification of Aloperine as an anti-apoptotic Bcl2 protein inhibitor in glioma cells.PeerJ · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
As a step toward developing novel anti-HIV agents, we have identified a class of quinolizidines, including aloperine, that inhibit HIV at 1-5 μM by blocking viral entry. In this study, we have optimized the structure of aloperine and derived compounds with markedly improved activity. Our structural optimization has yielded an aloperine derivative
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.